Antitumorigenic effect of proteasome inhibitors on insulinoma cells

Endocrinology

Volumn 146, Issue 4, 2005, Pages 1718-1726

  Størling, Joachim ^a   Allaman Pillet, Nathalie ^b   Karlsen, Allan E ^a   Billestrup, Nils ^a   Bonny, Christophe ^b   Mandrup Poulsen, Thomas ^a,c  

^a STENO DIABETES CENTER   (Denmark)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CASPASE 3; CYTOKINE; INSULIN; LACTACYSTIN; N ACETYLLEUCYLLEUCYLNORLEUCINAL; PROTEASOME INHIBITOR; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INTERACTING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL LINE; CELL PROTECTION; CELL STRAIN BETA TC3; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; IN VITRO STUDY; INFLAMMATION; INSULIN RELEASE; INSULINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ACETYLCYSTEINE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CELL LINE, TUMOR; CYSTEINE PROTEINASE INHIBITORS; INSULINOMA; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUPEPTINS; MICE; PANCREATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 15444367891     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2004-0963     Document Type: Article

References (37)

1. Brentjens R, Saltz L 2001 Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am 81:527-542
2. Burns AR, Dackiw AP 2003 Insulinoma. Curr Treat Options Oncol 4:309-317
3. Schwartz AL, Ciechanover A 1999 The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 50:57-74
4. Orlowski RZ 1999 The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 6:303-313
5. Almond JB, Cohen GM 2002 The proteasome: a novel target for cancer chemotherapy. Leukemia 16:433-443
6. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ 2003 The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316-6325
7. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR 2002 A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511
8. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL 2002 Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427
9. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC 2003 A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617
10. Davis RJ 2000 Signal transduction by the JNK group of MAP kinases. Cell 103:239-252
11. Chang L, Karin M 2001 Mammalian MAP kinase signalling cascades. Nature 410:37-40
12. Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C, Gillieron C, Boschert U, Vial-Knecht E, Martinou JC, Arkinstall S 1997 Bcl-2 undergoes phosphorylarion by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J Biol Chem 272:25238-25242
13. Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q, Cheng K, Chen YN, Campbell A, Sudha T, Yuan ZM, Narula J, Weichselbaum R, Nalin C, Kufe D 2000 Translation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J Biol Chem 275:322-327
14. Ammendrup A, Maillard A, Nielsen K, Andersen NA, Serup P, Madsen OD, Mandrup-Poulsen T, Bonny C 2000 The c-Jun amino-terminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic β-cells. Diabetes 49:1468-1476
15. Bonny C, Oberson A, Steinmann M, Schorderet DF, Nicod P, Waeber G 2000 IB1 reduces cytokine-induced apoptosis of insulin-secreting cells. J Biol Chem 275:16466-16472
16. Bonny C, Nicod P, Waeber G 1998 IB1, a JIP-1-related nuclear protein present in insulin-secreting cells. J Biol Chem 273:1843-1846
17. Dupraz P, Rinsch C, Pralong WF, Rolland E, Zufferey R, Trono D, Thorens B 1999 Lentivirus-mediated Bcl-2 expression in βTC-tet cells improves resistance to hypoxia and cytokine-induced apoptosis while preserving in vitro and in vivo control of insulin secretion. Gene Ther 6:1160-1169
18. Nikulina MA, Sandhu N, Shamim Z, Andersen NA, Oberson A, Dupraz P, Thorens B, Karlsen AE, Bonny C, Mandrup-Poulsen T 2003 The JNK binding domain of islet-brain 1 inhibits IL-1 induced JNK activity and apoptosis but not the transcription of key proapoptotic or protective genes in insulin-secreting cell lines. Cytokine 24:13-24
19. Nielsen JH, Linde S, Welinder BS, Billestrup N, Madsen OD 1989 Growth hormone is a growth factor for the differentiated pancreatic β-cell. Mol Endocrinol 3:165-173
20. Nielsen K, Karlsen AE, Deckert M, Madsen OD, Serup P, Mandrup-Poulsen T, Nerup J 1999 β-Cell maturation leads to in vitro sensitivity to cytotoxins. Diabetes 48:2324-2332
21. Meriin AB, Gabai VL, Yaglom J, Shifrin VI, Sherman MY 1998 Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis. J Biol Chem 273:6373-6379
22. MacFarlane M, Cohen GM, Dickens M 2000 JNK (c-Jun N-terminal kinase) and p38 activation in receptor-mediated and chemically-induced apoptosis of T-cells: differential requirements for caspase activation. Biochem J 348(Pt 1): 93-101
23. Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL, Davis RJ 1997 A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277:693-696
24. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL 1995 Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268:726-731
25. Eto A, Akita Y, Saido TC, Suzuki K, Kawashima S 1995 The role of the calpain-calpastatin system in thyrotropin-releasing hormone-induced selective down-regulation of a protein kinase C isozyme, nPKC epsilon, in rat pituitary GH4C1 cells. J Biol Chem 270:25115-25120
26. Haefliger JA, Tawadros T, Meylan L, Gurun SL, Roehrich ME, Martin D, Thorens B, Waeber G 2003 The scaffold protein IB1/JIP-1 is a critical mediator of cytokine-induced apoptosis in pancreatic β cells. J Cell Sci 116:1463-1469
27. Lopes UG, Erhardt P, Yao R, Cooper GM 1997 p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272:12893-12896
28. Naujokat C, Sezer O, Zinke H, Leclere A, Hauptmann S, Possinger K 2000 Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur J Haematol 65:221-236
29. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S, Kikuchi H 1995 Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 217:1070-1077
30. Shinohara K, Tomioka M, Nakano H, Tone S, Ito H, Kawashima S 1996 Apoptosis induction resulting from proteasome inhibition. Biochemical J 317(Pt 2):385-388
31. Drexler HC 1997 Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 94:855-860
32. Wojcik C, Stoklosa T, Giermasz A, Golab J, Zagozdzon R, Kawiak J, Wilk S, Komar A, Kaca A, Malejczyk J, Jakobisiak M 1997 Apoptosis induced in 11210 leukemia-cells by an inhibitor of the chymotrypsin-like activity of the proteasome. Apoptosis 2:455-462
33. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H 2004 Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 95:176-180
34. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC 2003 Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530-1534
35. Eizirik DL, Mandrup-Poulsen T 2001 A choice of death-the signal-transduction of immune-mediated β-cell apoptosis. Diabetologia 44:2115-2133
36. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T 2003 Inflammatory mediators and islet β-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 81:455-470
37. Yamin TT, Miller DK 1997 The interleukin-1 receptor-associated kinase is degraded by proteasomes following its phosphorylation. J Biol Chem 272:21540-21547